BACKGROUND: We aimed to evaluate the efficiency and safety of cis/ @entity3003 plus @entity136 , which was previously used for @entity2615 but with no recorded proof of its efficiency, compared with cis/ @entity3003 plus pemetrexed, which is known to be effective in @entity2615 , in comparable historical groups of @entity3620 . METHODS: One hundred and sixteen @entity1 received cis/ @entity3003 plus pemetrexed (group 1), while 30 @entity1 received cis/ @entity3003 plus @entity136 (group 2) between June 1999 and June 2012. The two groups were compared in terms of median survival and adverse events to chemotherapy. RESULTS: The mean ages of groups 1 and 2 were 60.7 and 60.8  years, respectively. Most of the @entity1 (78.1  %) had @entity5 , and 47  % of the @entity1 had stage IV disease. There was no difference between the two groups in terms of age, gender, asbestos exposure, histology, stage, Karnofsky performance status, presence of pleurodesis, prophylactic radiotherapy, second-line chemotherapy and  median hemoglobin and serum  albumin levels. The median survival time from diagnosis to @entity204 or the last day of follow up with a 95  % confidence interval was 12        0.95  months (95 % CI: 10.15-13.85) for group 1 and 11.0        1.09  months (95 % CI: 8.85-13.15) for group 2 (Log-Rank: 0.142; p   =   0.706). The median survival time from treatment to @entity204 or the last day of follow-up with a 95  % confidence interval was 11.0        0.99  months (95 % CI: 9.06-12.94) for group 1 and 11.0        1.52  months (95 % CI: 8.02-13.97) for group 2 (Log-Rank: 0.584; p   =   0.445). The stage and Karnofsky performance status were found to be significant variables on median survival time by univariate analysis. After adjusting for the stage and Karnofsky performance status, the chemotherapy schema was not impressive on median survival time (OR: 0.837; 95 % CI: 0.548-1.277; p   =   0.409). The progression free survival was 7.0        0.61  months for group I and 6.0        1.56  months for group II (Log-Rank: 0.522; p   =   0.470). The treatment was generally well tolerated, and the side effects were similar in both groups. CONCLUSIONS: The study indicates that @entity902 -based @entity136 is effective and a safe schema in @entity3620 . Further research should include large randomized phase III trials comparing these agents.

The effectiveness and safety of XXXX -based pemetrexed and @entity902 -based @entity136 treatment in @entity1 with @entity3620 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['epithelial type tumors'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesothelioma'] @entity3620 :: ('MESH:C562839', 'Disease') :: ['malignant pleural mesothelioma'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity902 :: (MESH:D010984,Chemical) :: ['platinum']
